Hengrui Pharma

EDITORIAL CONTENTS (incl. Podcasts, Webinars)

• Podcast: Drug Fix: Leucovorin’s Resurrection, PhRMA’s Leadership Change (Listen)
• Webinar: Beyond GLP‑1s: Mapping the Next Generation of Obesity Therapeutics (2pm GMT, May 26 | Register)
• Webinar: Navigating US FDA Approval Standards for Rare Diseases: What’s Happened and What’s Next (2pm GMT, June 11 | Register)

DEALS & FINANCING (incl. M&As, Licensing, Financing)

• M&A: Sun Pharma signs Definitive Agreement to Acquire Organon for $11.75B
• M&A: Eli Lilly To Buy Kelonia For Up To $7B
• M&A: Gilead To Acquire Tubulis For Up To $5B
• Licensing: Eli Lilly, Profluent Ally In Rare Diseases totalling $2.25B
• Licensing: Regeneron Enters Radiopharm Space Through Deal with Telix totalling $2.18B ($40M upfront)
• Licensing: Huahui Health and BeOne Medicines Enter into a Global Exclusive Option, License and Collaboration Agreement for HH160 totalling $2.02B ($20M upfront)
• Financing: Kailera Therapeutics Nets $668.4M in Initial Public Offering; Overallotment Fully Exercised
• Financing: Beeline Medicines Raises $300M in Series A Round
• Financing: Sidewinder Therapeutics Brings in $137M in Series B Round

KEY R&D EVENTS (incl. Top-line Readouts, Analyst Commentary, Approval/CRL)

• Positive: Revolution Medicines | A breakthrough for RAS-driven pancreatic cancer: daraxonrasib doubles survival versus chemotherapy
• Positive: AstraZeneca | Truqap ODAC Vote - First Targeted AKT Inhibitor Moves Closer to Prostate Cancer Approval
• Positive: CorMedix | Rezzayo (rezafungin) shows potential for antifungal prophylaxis during HSCT
• Positive: Spyre Therapeutics | Positive Phase II SKYLINE Part A induction results strengthen SPY001's potential as a best-in-class α4β7 antibody in ulcerative colitis
• Positive: NervGen | FDA alignment strengthens NervGen’s Phase 3 path for NVG-291 in chronic tetraplegia
• Negative: Compass | High crossover prevents tovecimig from achieving OS result in COMPANION-002 to send Compass stock crashing
• Negative: AstraZeneca | Strong efficacy, weak strategy: ODAC blocks camizestrant's first-line ESR1 mutation play
• Negative: Immunovant | Batoclimab misses primary endpoints in two Phase III thyroid eye disease trials

RESEARCH REPORTS (incl. Forecast, Thought Leadership, KOL Interview)

• Report: 2025 Deal-making Roundup (Link)
• Report: Gene, Cell, & RNA Therapy Landscape Q1 2026
• Report: A Guide to Patient Engagement & Recruitment Solutions
• Report: The 2026 Playbook Regulatory Leaders Can’t Afford To Miss
• Report: Q1 2026 Round Up: Proceed…With Caution
• Report: Epi & Market Forecast - Hidradenitis Suppurativa | Chronic Myeloid Leukemia
• Report: KOL Interview - Acute Lymphoblastic Leukemia | Dry Eye Syndrome | Hidradenitis Suppurativa | Idiopathic Pulmonary Fibrosis

Note: Require research support on scientific meetings not under below list? Submit your inquiry via Ask the Analyst!

Trialtrove分析师团队每年审阅全球160+医学年会的数千篇摘要披露，并在经过数据审核后将相关信息收录于数据库，其中包括：临床数据披露、临床方案更新、项目状态、入组进度等信息。下列表格为2021年至今全球各大领域重要医学会议的检索链接，以便快速找到有在某会议中披露最新动态的临床试验。

注：若想查阅未在下列范围内的医学会议，欢迎使用Ask the Analyst服务寻求辅助。